Dual-targeting CRISPR-CasRx Reduces C9orf72 ALS/FTD Sense and Antisense Repeat RNAs in Vitro and in Vivo

The most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) is an intronic GC repeat expansion in C9orf72. The repeats undergo bidirectional transcription to produce sense and antisense repeat RNA species, which are translated into dipeptide repeat proteins (DPRs). As toxicity has been associated with both sense and antisense repeat-derived RNA and DPRs, targeting both strands may provide the most effective therapeutic strategy. CRISPR-Cas13 systems mature their own guide arrays, allowing targeting of multiple RNA species from a single construct. We show CRISPR-Cas13d variant CasRx effectively reduces overexpressed C9orf72 sense and antisense repeat transcripts and DPRs in HEK cells. In C9orf72 patient-derived iPSC-neuron lines, CRISPR-CasRx reduces endogenous sense and antisense repeat RNAs and DPRs and protects against glutamate-induced excitotoxicity. AAV delivery of CRISPR-CasRx to two distinct C9orf72 repeat mouse models significantly reduced both sense and antisense repeat-containing transcripts. This highlights the potential of RNA-targeting CRISPR systems as therapeutics for C9orf72 ALS/FTD.

References

Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

Yan W, Chong S, Zhang H, Makarova K, Koonin E, Cheng D . Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein. Mol Cell. 2018; 70(2):327-339.e5. PMC: 5935466. DOI: 10.1016/j.molcel.2018.02.028. View

Gendron T, Bieniek K, Zhang Y, Jansen-West K, Ash P, Caulfield T . Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013; 126(6):829-44. PMC: 3830741. DOI: 10.1007/s00401-013-1192-8. View

Soneson C, Love M, Robinson M . Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2016; 4:1521. PMC: 4712774. DOI: 10.12688/f1000research.7563.2. View

Liu Y, Dodart J, Tran H, Berkovitch S, Braun M, Byrne M . Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun. 2021; 12(1):847. PMC: 7870851. DOI: 10.1038/s41467-021-21112-8. View

Balendra R, Isaacs A . C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018; 14(9):544-558. PMC: 6417666. DOI: 10.1038/s41582-018-0047-2. View

Mizielinska S, Gronke S, Niccoli T, Ridler C, Clayton E, Devoy A . C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014; 345(6201):1192-1194. PMC: 4944841. DOI: 10.1126/science.1256800. View

Mathiesen S, Lock J, Schoderboeck L, Abraham W, Hughes S . CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain. Mol Ther Methods Clin Dev. 2020; 19:447-458. PMC: 7683292. DOI: 10.1016/j.omtm.2020.10.011. View

Fernandopulle M, Prestil R, Grunseich C, Wang C, Gan L, Ward M . Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol. 2018; 79(1):e51. PMC: 6993937. DOI: 10.1002/cpcb.51. View

10.

Prudencio M, Humphrey J, Pickles S, Brown A, Hill S, Kachergus J . Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020; 130(11):6080-6092. PMC: 7598060. DOI: 10.1172/JCI139741. View

11.

Bush J, Aikawa H, Fuerst R, Li Y, Ursu A, Meyer S . Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(GC) repeat expansion in vitro and in vivo ALS models. Sci Transl Med. 2021; 13(617):eabd5991. PMC: 9533739. DOI: 10.1126/scitranslmed.abd5991. View

12.

Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah S, Shi Y . Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014; 84(6):1213-25. PMC: 4632245. DOI: 10.1016/j.neuron.2014.12.010. View

13.

Irwin K, Jasin P, Braunstein K, Sinha I, Garret M, Bowden K . A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nat Med. 2024; 30(2):382-393. PMC: 10878965. DOI: 10.1038/s41591-023-02788-5. View

14.

Chew J, Gendron T, Prudencio M, Sasaguri H, Zhang Y, Castanedes-Casey M . Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015; 348(6239):1151-4. PMC: 4692360. DOI: 10.1126/science.aaa9344. View

15.

Melamed Z, Lopez-Erauskin J, Baughn M, Zhang O, Drenner K, Sun Y . Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019; 22(2):180-190. PMC: 6348009. DOI: 10.1038/s41593-018-0293-z. View

16.

Boivin M, Pfister V, Gaucherot A, Ruffenach F, Negroni L, Sellier C . Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. EMBO J. 2020; 39(4):e100574. PMC: 7024836. DOI: 10.15252/embj.2018100574. View

17.

Martier R, Liefhebber J, Miniarikova J, van der Zon T, Snapper J, Kolder I . Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol Ther Nucleic Acids. 2019; 14:593-608. PMC: 6378669. DOI: 10.1016/j.omtn.2019.01.010. View

18.

Xu D, Vincent A, Gonzalez-Gutierrez A, Aleyakpo B, Anoar S, Giblin A . A monocarboxylate transporter rescues frontotemporal dementia and Alzheimer's disease models. PLoS Genet. 2023; 19(9):e1010893. PMC: 10513295. DOI: 10.1371/journal.pgen.1010893. View

19.

Hughes M, Nelvagal H, Coombe-Tennant O, Smith D, Smith C, Massaro G . A Novel Small Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann-Pick Type C1 Disease. Cells. 2023; 12(12). PMC: 10296851. DOI: 10.3390/cells12121619. View

20.

van den Berg L, Rothstein J, Shaw P, Babu S, Benatar M, Bucelli R . Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurol. 2024; 23(9):901-912. DOI: 10.1016/S1474-4422(24)00216-3. View